Histone deacetylases as regulators of inflammation and immunity

Trends in Immunology

Volumn 32, Issue 7, 2011, Pages 335-343

  Shakespear, Melanie R ^a   Halili, Maria A ^a   Irvine, Katharine M ^a   Fairlie, David P ^a   Sweet, Matthew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LYSINE; ROMIDEPSIN; TOLL LIKE RECEPTOR; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; APOPTOSIS; ARTHRITIS; ATHEROSCLEROSIS; B LYMPHOCYTE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CHRONIC DISEASE; CYTOKINE PRODUCTION; ENTERITIS; GENE TARGETING; GRAFT VERSUS HOST REACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LUNG DISEASE; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SEPTIC SHOCK; T CELL LYMPHOMA; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 79959804516     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.04.001     Document Type: Review

References (81)

1. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
2. Yang W.M., et al. Functional domains of histone deacetylase-3. J. Biol. Chem. 2002, 277:9447-9454.
3. Yang X.J., et al. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9:206-218.
4. Martin M., et al. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007, 26:5450-5467.
5. Haberland M., et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
6. Guardiola A.R., et al. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 2002, 277:3350-3356.
7. Baek Y.S., et al. Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells. BMC Immunol. 2009, 10:18.
8. Ueki N., et al. Ski can negatively regulates macrophage differentiation through its interaction with PU.1. Oncogene 2008, 27:300-307.
9. Aung H.T., et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 2006, 20:1315-1327.
10. Halili M.A., et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J. Leukoc. Biol. 2010, 87:1103-1114.
11. Bode K.A., et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007, 122:596-606.
12. Brogdon J.L., et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
13. Roger T., et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2010, 117:1205-1217.
14. Cao W., et al. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med. 2008, 205:1491-1503.
15. Gabriele L., et al. The role of the interferon regulatory factor (IRF) family in dendritic cell development and function. Cytokine Growth Factor Rev. 2007, 18:503-510.
16. Salvi V., et al. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology 2010, 215:756-761.
17. Nencioni A., et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 2007, 13:3933-3941.
18. Caillaud A., et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 2002, 277:49417-49421.
19. Nusinzon I., et al. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol. Cell. Biol. 2006, 26:3106-3113.
20. Peyssonnaux C., et al. Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J. Immunol. 2007, 178:7516-7519.
21. Cramer T., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
22. Kim S.H., et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep. 2007, 17:647-651.
23. Qian D.Z., et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006, 66:8814-8821.
24. Kato H., et al. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J. Biol. Chem. 2004, 279:41966-41974.
25. Foster S.L., et al. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447. 972-928.
26. Lu J., et al. Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine 2005, 31:46-51.
27. Deng W.G., et al. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004, 103:2135-2142.
28. Gilchrist M., et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006, 441:173-178.
29. Ashburner B.P., et al. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 2001, 21:7065-7077.
30. Choi Y.S., et al. PI3-kinase and PDK-1 regulate HDAC1-mediated transcriptional repression of transcription factor NF-kappaB. Mol. Cells 2005, 20:241-246.
31. Elsharkawy A.M., et al. The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J. Hepatol. 2010, 53:519-527.
32. Chen L., et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
33. Pakala S.B., et al. Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J. Biol. Chem. 2010, 285:23590-23597.
34. Osoata G.O., et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem. Biophys. Res. Commun. 2009, 384:366-371.
35. Ito K., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 2006, 203:7-13.
36. Into T., et al. Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by sequestosome 1 and histone deacetylase 6. J. Biol. Chem. 2010, 285:35759-35769.
37. Ghisletti S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
38. Kovacs J.J., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
39. De Bosscher K., et al. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol. 2009, 23:281-291.
40. Tang X., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
41. Kramer O.H., et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009, 23:223-235.
42. Chang H.M., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9578-95783.
43. Sakamoto S., et al. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J. Biol. Chem. 2004, 279:40362-40367.
44. Klampfer L., et al. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 2004, 279:30358-30368.
45. Nusinzon I., et al. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14742-14747.
46. Zupkovitz G., et al. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol. 2006, 26:7913-7928.
47. Xu D., et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009, 30:802-816.
48. Bosisio D., et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 2008, 84:1540-1548.
49. Villagra A., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 2009, 10:92-100.
50. Kong X., et al. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J. Mol. Cell. Cardiol. 2009, 46:292-299.
51. Zika E., et al. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol. 2003, 23:3091-3102.
52. Yamaguchi T., et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010, 24:455-469.
53. Zhang Y., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28:1688-1701.
54. Serrador J.M., et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004, 20:417-428.
55. Cabrero J.R., et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol. Biol. Cell 2006, 17:3435-3445.
56. Matthews S.A., et al. Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol. Cell. Biol. 2006, 26:1569-1577.
57. Dequiedt F., et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J. Exp. Med. 2005, 201:793-804.
58. Kao H.Y., et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 2001, 276:47496-47507.
59. Kasler H.G., et al. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol. Cell. Biol. 2007, 27:5184-5200.
60. Kasler H.G., et al. Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes. J. Immunol. 2011, 186:4782-4793.
61. Navarro M.N., et al. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat. Immunol. 2011, 12:352-361.
62. de Zoeten E.F., et al. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
63. Li B., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4571-4576.
64. Tao R., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13:1299-1307.
65. Samanta A., et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14023-14027.
66. van Loosdregt J., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
67. de Zoeten E.F., et al. HDAC6 and HSP90 control the functions of Foxp3+ T-regulatory cells. Mol. Cell. Biol. 2011, [Epub ahead of print].
68. Han S., et al. Recruitment of histone deacetylase 4 by transcription factors represses interleukin-5 transcription. Biochem. J. 2006, 400:439-448.
69. Grausenburger R., et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J. Immunol. 2010, 185:3489-3497.
70. Bartl S., et al. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol. Cell. Biol. 1997, 17:5033-5043.
71. Bantscheff M., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 2011, 29:255-265.
72. Bradner J.E., et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2010, 6:238-243.
73. Halili M.A., et al. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 2009, 9:309-319.
74. Choi J.H., et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2404-2409.
75. Huang B., et al. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell. Signal. 2010, 22:1282-1290.
76. Buerki C., et al. Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res. 2008, 36:1665-1680.
77. Yang X.D., et al. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J. 2009, 28:1055-1066.
78. Desterro J.M., et al. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 1998, 2:233-239.
79. Yang X.D., et al. Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol. Cell. Biol. 2010, 30:2170-2180.
80. Downes M., et al. Identification of a nuclear domain with deacetylase activity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10330-10335.
81. Fischle W., et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 2001, 276:35826-35835.